Literature DB >> 22395298

Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis.

Sandra Gustafsson1, Elisabet Ihse, Michael Y Henein, Per Westermark, Per Lindqvist, Ole B Suhr.   

Abstract

BACKGROUND: Liver transplantation (LTx) is an accepted treatment for hereditary transthyretin (TTR) amyloidosis (ATTR). However, unforeseen heart complications, especially a rapid development of cardiomyopathy after LTx has affected mortality and morbidity. Recently, a relationship between ATTR-fibril composition and cardiomyopathy has been noted. The aim of this study was to investigate whether development of cardiomyopathy and heart failure in LTx ATTR amyloid patients is related to amyloid fibril composition.
METHODS: Twenty-four patients with hereditary ATTR amyloidosis who had undergone LTx and have had their amyloid fibril type tested were available for the study. They had been examined by echocardiography including tissue Doppler and speckle tracking echocardiography before and after LTx. Patients were divided into two groups according to fibril composition, 10 patients with type A fibrils (a mixture of truncated and full-length TTR) and 14 patients with type B fibrils (full-length TTR fibrils only). There was no difference in time to the follow-up echocardiography between the two groups.
RESULTS: After LTx, the group consisting of type A patients developed symptoms of heart failure and with reduced systolic and diastolic ventricular function as shown by echocardiography, whereas no similar deterioration was noted for the group of patients with type B fibrils.
CONCLUSION: Patients with type A fibrils deteriorate an already existing cardiomyopathy and heart failure after LTx, in contrast to patients with type B fibrils. These results might have significant clinical implications in optimizing best patients selection criteria for LTx.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22395298     DOI: 10.1097/TP.0b013e31824b3749

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  24 in total

Review 1.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

2.  A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.

Authors:  Mitsuharu Ueda; Masamitsu Okada; Mineyuki Mizuguchi; Barbara Kluve-Beckerman; Kyosuke Kanenawa; Aito Isoguchi; Yohei Misumi; Masayoshi Tasaki; Akihiko Ueda; Akinori Kanai; Ryoko Sasaki; Teruaki Masuda; Yasuteru Inoue; Toshiya Nomura; Satoru Shinriki; Tsuyoshi Shuto; Hirofumi Kai; Taro Yamashita; Hirotaka Matsui; Merrill D Benson; Yukio Ando
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 3.  Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.

Authors:  Gunilla T Westermark; Marcus Fändrich; Katarzyna Lundmark; Per Westermark
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

Review 4.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 5.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

Review 6.  Targeted treatments of AL and ATTR amyloidosis.

Authors:  Pranav Chandrashekar; Anish K Desai; Barry H Trachtenberg
Journal:  Heart Fail Rev       Date:  2021-11-16       Impact factor: 4.654

Review 7.  Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.

Authors:  Deepa M Gopal; Frederick L Ruberg; Omar K Siddiqi
Journal:  Curr Heart Fail Rep       Date:  2019-10

8.  Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

Authors:  P Patrizia Mangione; Riccardo Porcari; Julian D Gillmore; Piero Pucci; Maria Monti; Mattia Porcari; Sofia Giorgetti; Loredana Marchese; Sara Raimondi; Louise C Serpell; Wenjie Chen; Annalisa Relini; Julien Marcoux; Innes R Clatworthy; Graham W Taylor; Glenys A Tennent; Carol V Robinson; Philip N Hawkins; Monica Stoppini; Stephen P Wood; Mark B Pepys; Vittorio Bellotti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

Review 9.  Recent advances in transthyretin amyloidosis therapy.

Authors:  Mitsuharu Ueda; Yukio Ando
Journal:  Transl Neurodegener       Date:  2014-09-13       Impact factor: 8.014

10.  (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Authors:  Björn Pilebro; Ole B Suhr; Ulf Näslund; Per Westermark; Per Lindqvist; Torbjörn Sundström
Journal:  Ups J Med Sci       Date:  2016-02-05       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.